The Treatment of Senile Dementia Associated with Cerebrovascular Insufficiency: A Comparative Study of Buflomedil and Dihydrogenated Ergot Alkaloids

Abstract

Seventy-six patients took part in a randomized, comparative study of the efficacy of buflomedil hydrochloride and dihydrogenated ergot alkaloids in the treatment of senile dementia associated with cerebrovascular insufficiency. Efficacy was assessed by the patients' performance in four psychometric tests. The results showed that a trend in favour of the buflomedil group in three of the tests became statistically significant in the fourth. Both drugs appeared to be safe, causing no marked adverse reactions. In conclusion, buflomedil is as effective or more effective than dihydrogenated ergot alkaloids in the treatment of senile dementia associated with cerebrovascular insufficiency and could prove a valuable addition to long-term therapy if further studies support the trend shown in this study.

The Families of Cognition Enhancers

“…The effectiveness of buflomedil has also been assessed in demented patients (Bel/oi et al, 1987;Karoutas et al, 1987;Bossi et al, 1985;Jansen et al, 1985;Levinson et al, 1985). The effect of buflomedil on neurotransmitters in the striatum and in substantia nigra of rats have been published recently (Koda et al, 1988).…”

Drug treatments for cognitive impairment due to ageing and disease: Current and future strategies

“…Oxpentifylline seems to reduce blood viscosity and has been reported to have a modestly beneficial effect in arteriosclerotic dementia (Ghose, 1987). Bufluomedil has also been reported to improve the microcirculation and to benefit patients with cerebral arteriosclerosis (Jansen et al, 1985;Karoutas et al, 1987).…”